

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

Purified anti-human CD3

RRID:AB_571926

Type: Antibody

Proper Citation

BioLegend Cat# 317301, RRID:AB_571926

Antibody Information

URL: http://antibodyregistry.org/AB_571926

Proper Citation: BioLegend Cat# 317301, RRID:AB_571926

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F

Antibody Name: Purified anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_571926

Vendor: BioLegend

Catalog Number: 317301

Alternative Catalog Numbers: 317302

Record Creation Time: 20250820T053009+0000

Record Last Update: 20250820T214239+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD3.

No alerts have been found for Purified anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.

Moro A, et al. (2025) Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming. *iScience*, 28(6), 112553.

Teijeira A, et al. (2024) Low-Dose Ionizing γ -Radiation Elicits the Extrusion of Neutrophil Extracellular Traps. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4131.

Lindner S, et al. (2024) Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. *Nature microbiology*, 9(3), 614.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. *Immunity*, 57(9), 2232.

Jackson JW, et al. (2024) An antibody that inhibits TGF- β 1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. *Science signaling*, 17(844), eadn6052.

Gubser C, et al. (2023) GTR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy. *iScience*, 26(11), 108165.

Meadows AM, et al. (2023) N-arachidonylglycine is a caloric state-dependent circulating metabolite which regulates human CD4+T cell responsiveness. *iScience*, 26(5), 106578.

Corcoran M, et al. (2023) Archaic humans have contributed to large-scale variation in modern human T cell receptor genes. *Immunity*, 56(3), 635.

Nalio Ramos R, et al. (2022) Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. *Cell*, 185(7), 1189.

Hu X, et al. (2021) M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA. *British journal of pharmacology*, 178(6), 1445.

Pan Y, et al. (2021) The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF- κ B-mediated inflammation. *British journal of pharmacology*, 178(24), 4907.

Herati RS, et al. (2021) Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways. *Cell reports. Medicine*, 2(5), 100262.

Kaufmann M, et al. (2021) Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. *Med (New York, N.Y.)*, 2(3), 296.